vs
Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Community Healthcare Trust Inc is the larger business by last-quarter revenue ($31.5M vs $20.4M, roughly 1.5× Sight Sciences, Inc.). Community Healthcare Trust Inc runs the higher net margin — 8.1% vs -20.4%, a 28.5% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs 4.8%). Over the past eight quarters, Community Healthcare Trust Inc's revenue compounded faster (7.0% CAGR vs 2.9%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CHCT vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.5M | $20.4M |
| Net Profit | $2.5M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 8.1% | -20.4% |
| Revenue YoY | 4.8% | 6.9% |
| Net Profit YoY | 60.2% | 64.9% |
| EPS (diluted) | — | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $31.5M | — | ||
| Q4 25 | $30.9M | $20.4M | ||
| Q3 25 | $31.1M | $19.9M | ||
| Q2 25 | $29.1M | $19.6M | ||
| Q1 25 | $30.1M | $17.5M | ||
| Q4 24 | $29.3M | $19.1M | ||
| Q3 24 | $29.6M | $20.2M | ||
| Q2 24 | $27.5M | $21.4M |
| Q1 26 | $2.5M | — | ||
| Q4 25 | $14.4M | $-4.2M | ||
| Q3 25 | $1.6M | $-8.2M | ||
| Q2 25 | $-12.6M | $-11.9M | ||
| Q1 25 | $1.6M | $-14.2M | ||
| Q4 24 | $1.8M | $-11.8M | ||
| Q3 24 | $1.7M | $-11.1M | ||
| Q2 24 | $-10.4M | $-12.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | -18.0% | ||
| Q3 25 | — | -39.7% | ||
| Q2 25 | — | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | — | -59.2% |
| Q1 26 | 8.1% | — | ||
| Q4 25 | 46.6% | -20.4% | ||
| Q3 25 | 5.3% | -41.0% | ||
| Q2 25 | -43.2% | -61.0% | ||
| Q1 25 | 5.3% | -80.8% | ||
| Q4 24 | 6.3% | -62.1% | ||
| Q3 24 | 5.9% | -54.9% | ||
| Q2 24 | -37.9% | -57.7% |
| Q1 26 | — | — | ||
| Q4 25 | $0.52 | $-0.07 | ||
| Q3 25 | $0.03 | $-0.16 | ||
| Q2 25 | $-0.50 | $-0.23 | ||
| Q1 25 | $0.03 | $-0.28 | ||
| Q4 24 | $0.04 | $-0.23 | ||
| Q3 24 | $0.04 | $-0.22 | ||
| Q2 24 | $-0.42 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $421.3M | $63.9M |
| Total Assets | $1.0B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.6M | — | ||
| Q4 25 | $3.3M | $92.0M | ||
| Q3 25 | $3.4M | $92.4M | ||
| Q2 25 | $4.9M | $101.5M | ||
| Q1 25 | $2.3M | $108.8M | ||
| Q4 24 | $4.4M | $120.4M | ||
| Q3 24 | $2.8M | $118.6M | ||
| Q2 24 | $734.0K | $118.2M |
| Q1 26 | — | — | ||
| Q4 25 | $532.2M | $42.4M | ||
| Q3 25 | $530.1M | $42.4M | ||
| Q2 25 | $500.1M | $42.4M | ||
| Q1 25 | $496.0M | $42.4M | ||
| Q4 24 | $486.0M | $40.0M | ||
| Q3 24 | $473.7M | $37.1M | ||
| Q2 24 | $457.6M | $35.0M |
| Q1 26 | $421.3M | — | ||
| Q4 25 | $429.4M | $63.9M | ||
| Q3 25 | $426.8M | $64.3M | ||
| Q2 25 | $437.8M | $70.0M | ||
| Q1 25 | $461.3M | $77.6M | ||
| Q4 24 | $476.0M | $87.5M | ||
| Q3 24 | $477.2M | $95.0M | ||
| Q2 24 | $497.8M | $101.6M |
| Q1 26 | $1.0B | — | ||
| Q4 25 | $990.8M | $115.3M | ||
| Q3 25 | $987.3M | $116.3M | ||
| Q2 25 | $966.3M | $122.0M | ||
| Q1 25 | $985.1M | $129.7M | ||
| Q4 24 | $992.6M | $142.8M | ||
| Q3 24 | $981.8M | $143.6M | ||
| Q2 24 | $983.2M | $149.7M |
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | 0.66× | ||
| Q3 25 | 1.24× | 0.66× | ||
| Q2 25 | 1.14× | 0.61× | ||
| Q1 25 | 1.08× | 0.55× | ||
| Q4 24 | 1.02× | 0.46× | ||
| Q3 24 | 0.99× | 0.39× | ||
| Q2 24 | 0.92× | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $56.4M | $-1.8M | ||
| Q3 25 | $12.7M | $-8.7M | ||
| Q2 25 | $13.8M | $-7.5M | ||
| Q1 25 | $14.4M | $-11.6M | ||
| Q4 24 | $58.9M | $-3.5M | ||
| Q3 24 | $13.8M | $362.0K | ||
| Q2 24 | $16.7M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $35.9M | $-2.0M | ||
| Q3 25 | $7.6M | $-8.9M | ||
| Q2 25 | $9.6M | $-7.8M | ||
| Q1 25 | $9.7M | — | ||
| Q4 24 | $34.2M | $-3.6M | ||
| Q3 24 | $6.7M | $311.0K | ||
| Q2 24 | $9.5M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | 116.0% | -9.7% | ||
| Q3 25 | 24.6% | -44.7% | ||
| Q2 25 | 32.9% | -39.6% | ||
| Q1 25 | 32.3% | — | ||
| Q4 24 | 116.9% | -18.9% | ||
| Q3 24 | 22.5% | 1.5% | ||
| Q2 24 | 34.7% | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | 66.3% | 0.8% | ||
| Q3 25 | 16.3% | 0.9% | ||
| Q2 25 | 14.5% | 1.1% | ||
| Q1 25 | 15.6% | 0.0% | ||
| Q4 24 | 84.1% | 0.7% | ||
| Q3 24 | 24.2% | 0.3% | ||
| Q2 24 | 26.1% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.91× | — | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | — | ||
| Q4 24 | 32.14× | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHCT
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
